Everything you need to know before investing in PAR and CUV during the coronavirus.

Are you frustrated with the market acting like a rollercoaster? If yes, then you are not alone. Many smart investors, have had enough with the media suffocating the public on the coronavirus. Many investors are now basing their entire financial decision on what the media reports. Consequently, the coronavirus fear is beating down fundamentally strong […]

Why did Ex-NFL player Mitch Marrow call PAR’s drug life changing?

A silver lining in the current bearish decline is the opportunity to possibly enter strong stocks like Paradigm Biopharmaceuticals (ASX: PAR). PAR is one of Australia’s most talked-about biotechs of 2019 and 2020 so far. PAR strives to alleviate the suffering and cartilage degradation of Osteoarthritis patients through its repurposed drug Zilosul. Today we will […]

Here’s why PAR is worth watching now more than ever?

When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]